- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01309373
An Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia
February 13, 2012 updated by: Janssen-Cilag, S.A.
Epidemiological Study to Assess the Psychosocial and Symptomatic Remission and Community Integration Status in Patients With Schizophrenia (REINTEGRA Study)
The purpose of this study is to estimate the level of symptomatic and psychosocial remission of patients with schizophrenia and schizoaffective disorder in standard clinical practice as a function of the degree of adherence to antipsychotic treatment.
The secondary objectives are to study the level of community integration of the patients included in the study, and its influencing factors, to analyze the role of various sociodemographic factors, factors related to the course of disease and the psychopathological status of the patient in community integration and remission, to analyze the potential predictors of a favorable course (symptomatic and psychosocial remission) and a poor course (no symptomatic or psychosocial remission), to assess the impact of treatment adherence on the change in the functional and community integration status of patients (based on the occupation, independence level, and degree of disability variables), to assess the significance of premorbid (academic and social) adjustment in the symptomatic and functional remission and the community integration status of patients and to correlate the level of insight to the remission and integration status of patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a retrospective, cross-sectional, non-interventional observational, cohort epidemiological study conducted in the outpatient mental health facility setting in patients with schizophrenia.
The inclusion of two patient cohorts is contemplated, recruited in mental health facilities.
One cohort will involve patients estimated to have inadequate adherence to antipsychotic treatment, while the other will consist of patients with adequate adherence to such treatment.
N/A
Study Type
Observational
Enrollment (Actual)
1809
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Patients seen in Spanish outpatient mental health facilities, with schizophrenia or schizoaffective disorder
Description
Inclusion Criteria:
- Patients with schizophrenia or schizoaffective disorder being followed-up at a mental health facility
- Whose clinical records of recent years may be accessed
- Who has signed informed consent, stating that he/she understands the study purpose and requirements and gives consent to participate in the study
- In whom the psychiatrist and main caregiver may estimate the degree of adherence to antipsychotic treatment during the last two years
- Not hospitalized in acute disorder units in the last 12 months
Exclusion Criteria:
- Patients with psychiatric disease other than schizophrenia or schizoaffective disorder who have been diagnosed with severe to moderate mental retardation, organic disorders of personality, and/or severe and/or disabling neurological disease
- Patients who are actively participating in any clinical trial/study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
001
Patient assessment 2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale).
The BPRS scale will be used to assess the clinical integration of patients.
|
2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale).
The BPRS scale will be used to assess the clinical integration of patients.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2010
Study Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
March 3, 2011
First Submitted That Met QC Criteria
March 3, 2011
First Posted (Estimate)
March 7, 2011
Study Record Updates
Last Update Posted (Estimate)
February 14, 2012
Last Update Submitted That Met QC Criteria
February 13, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR016684
- RISSCH4248 (Other Identifier: Janssen-Cilag S.A., Spain)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Patient assessment
-
Jennifer HrabeRecruiting
-
Giresun UniversityCompletedPulmonary Artery HypertensionTurkey
-
Mayo ClinicCompleted
-
Ohio State University Comprehensive Cancer CenterRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
University of California, San FranciscoBristol-Myers Squibb FoundationCompletedStage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Malignant Neoplasm | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal... and other conditionsUnited States
-
University Hospital, Basel, SwitzerlandUniversity Hospital, Geneva; Medical University Innsbruck; Luzerner Kantonsspital and other collaboratorsRecruitingMyocardial Infarction | Myocardial Injury | Perioperative ComplicationSwitzerland, Austria
-
New York UniversityRecruiting
-
Kiskunhalas Semmelweis Hospital the Teaching Hospital...Szeged University; Budapest University of Technology and Economics; Hochschule...Not yet recruitingAcute Lung InjuryHungary
-
Abbott Medical OpticsCompleted
-
Abbott Medical OpticsCompleted